E. E. Brown

发表

Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen

J. Diallo, Stephen Boulton, S. Paludan, 2022, Molecular Therapy.

SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition

J. Diallo, Stephen Boulton, J. Bell, 2021, Biosensors and Bioelectronics.

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy

Takafumi N. Yamaguchi, P. Boutros, J. Diallo, 2022, Nature Communications.

Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection

J. Diallo, Stephen Boulton, J. Cailhier, 2021, Molecular Therapy.

Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry

A. Gingras, J. Diallo, Stephen Boulton, 2021, Molecular Therapy.

Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction

J. Diallo, Stephen Boulton, J. Bell, 2021, International journal of molecular sciences.

Characterization of Critical Determinants of ACE2-RBD Interaction

J. Diallo, Stephen Boulton, J. Bell, 2021, bioRxiv.

Nanoluciferase complementation-based biosensor reveals the importance of N- linked glycosylation of SARS-CoV-2 Spike for viral entry

A. Gingras, J. Diallo, Stephen Boulton, 2020 .

Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization

J. Diallo, J. Whelan, Stephen Boulton, 2020, Membranes.